CAC
FLNA

Cowen and Company’s Filana Therapeutics FLNA Stock Holding History

Cowen and Company’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,000
Closed -$26K – 714
2021
Q4 		$26K Sell
7,000
-5,500
-44% -$288K ﹤0.01% 503
2021
Q3 		$204K Buy
+12,500
New +$1.04M 0.01% 259

Other funds holding FLNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cowen and Company's FLNA Position: Q1 2024 in Review

Cowen and Company sold out of Filana Therapeutics (FLNA) in Q1 2024, closing a stake of 500,000 shares — an estimated $11.3M sold.

Cowen and Company first reported a position in FLNA in Q3 2021 and held it in 4 quarters. The position peaked at $11.3M in Q4 2023. 143 funds tracked by Wall St. Rank hold FLNA as of Q1 2024.

  • Cowen and Company reported no remaining Filana Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 500,000 Filana Therapeutics shares in Q1 2024, an estimated $11.3M.
  • Cowen and Company first reported a position in Filana Therapeutics in Q3 2021 and held it in 4 quarters.
  • Cowen and Company's Filana Therapeutics position peaked at $11.3M in Q4 2023.
  • 143 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.